Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
QuantumPharm, Inc. ( (HK:2228) ) just unveiled an announcement.
XtalPi Holdings Limited announced its annual results for the year ended December 31, 2024, reporting a 52.8% increase in revenue to RMB266.4 million and a narrowed adjusted net loss by 12.5% to RMB456.8 million. The company has reached the Commercial Company revenue threshold ahead of schedule, indicating a steady progression towards large-scale development. XtalPi’s implementation of AI tools and high-efficiency strategies has reduced its monthly average cash burn by 22.6%. The company is pioneering a shift in R&D paradigms with its ‘AI + Robotics’ framework, which enhances drug and materials development through advanced AI models and high-throughput experimentation, potentially disrupting various industries.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a Specialist Technology Company listed under Chapter 18C of the Stock Exchange. The company focuses on leveraging AI and robotics to innovate in the fields of drug and materials development, aiming to transform traditional R&D methodologies.
YTD Price Performance: -0.17%
Average Trading Volume: 111,870,525
Technical Sentiment Signal: Hold
For detailed information about 2228 stock, go to TipRanks’ Stock Analysis page.